Lyme disease vaccine research has entered a new phase as scientists examine what happens when healthy adults receive a second yearly booster of VLA15, a multivalent vaccine candidate designed to prevent infection with the bacteria responsible for Lyme borreliosis. The study, led by L. Wagner, V. Kadlecek, J. Skaroupkova and colleagues, is reported in Nature Communications in 2026 and focuses on the durability of immune protection after repeated vaccination.
Lyme borreliosis is caused primarily by bacteria belonging to the Borrelia burgdorferi sensu lato group. The organisms are transmitted to humans through the bites of infected Ixodes ticks. Because several medically important Borrelia species and strains circulate across different geographical regions, developing a broadly protective vaccine has been more complicated than targeting a single, genetically uniform pathogen. VLA15 was developed to address this diversity through a multivalent antigenic design.
The vaccine candidate targets outer surface protein A, or OspA, a molecule displayed on the surface of Borrelia while the bacterium is inside the tick. OspA has an important role in the organism’s survival within the tick midgut. When a vaccinated person is bitten, antibodies generated against OspA can enter the feeding tick along with the person’s blood. These antibodies may then bind to the bacteria before they migrate from the tick into human tissue, creating a prevention mechanism that acts at the vector–pathogen interface.
VLA15 incorporates OspA variants selected to represent six major serotypes associated with Lyme disease-causing Borrelia. By combining these antigenic targets, the candidate is intended to extend coverage beyond the regional limitations that affected earlier vaccine approaches. The strategy is particularly relevant because the distribution of Borrelia species and OspA serotypes differs between North America and Europe, while tick populations and disease risk are expanding or shifting in several areas.
The new report examines the effect of administering a second annual booster dose to healthy individuals who had already received previous VLA15 vaccinations. Booster doses are used to reinforce immune memory, a biological process in which long-lived B cells and antibody-producing cells respond more rapidly and intensely after renewed exposure to an antigen. In a vaccine program against a seasonal or intermittently encountered pathogen, the timing and frequency of such boosters can determine whether protection remains strong across successive years.
A key scientific issue is whether repeated exposure to the same multivalent antigen maintains or improves the quality of the antibody response. Antibody concentration is one important measurement, but protection can also depend on antibody affinity, the ability of antibodies to recognize multiple OspA variants, and their functional capacity to interfere with bacterial survival. Researchers may therefore evaluate immune responses against the vaccine’s component serotypes and examine whether the second yearly booster produces a broad and sustained response rather than simply increasing overall antibody levels temporarily.
The safety profile of repeated vaccination is another central consideration. Healthy participants provide a controlled population in which local reactions, systemic symptoms and other adverse events can be monitored over time. Repeated immunization can produce familiar short-term effects, such as pain at the injection site, fatigue or fever, but long-term vaccine development requires careful assessment of whether additional doses introduce unexpected safety signals. Studies of this type also help establish whether a future vaccination schedule would require annual boosters, less frequent reinforcement or a tailored approach based on immune-response data.
The VLA15 program is being developed against a backdrop of renewed interest in Lyme disease prevention. Lyme borreliosis is among the most frequently reported tick-borne infections in parts of North America and Europe, and its clinical presentation can range from the characteristic expanding skin lesion known as erythema migrans to neurological, cardiac and joint complications. Antibiotic treatment is generally effective when infection is recognized promptly, but delayed diagnosis can lead to prolonged illness and more complex medical care. A vaccine could reduce the number of infections before symptoms begin, complementing tick avoidance, protective clothing, repellents and early medical evaluation.
Because VLA15 remains a vaccine candidate, the findings from the second-booster study should be interpreted as part of a larger development pathway rather than as evidence that a licensed Lyme vaccine is already available. A study in healthy volunteers can provide critical information about immunogenicity and tolerability, but it does not by itself establish real-world protection against tick-transmitted infection. That question requires later-stage studies involving larger and more diverse populations, geographic exposure patterns and clinical endpoints. Nevertheless, understanding how immunity behaves after repeated annual vaccination is an essential step in designing a practical prevention strategy.
The Nature Communications report adds to the scientific record on whether a multivalent OspA vaccine can sustain broad immune recognition through repeated dosing. Its findings may influence future decisions about booster schedules, regional coverage and the selection of immune markers used to predict protection. For a disease transmitted by a complex vector and caused by several related bacterial lineages, the success of vaccination will depend not only on producing antibodies, but also on maintaining the right antibodies, against the right targets, for long enough to block transmission at the tick bite.
Subject of Research: Second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals
Article Title: A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals.
Article References: Wagner, L., Kadlecek, V., Skaroupkova, J. et al. A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals. Nature Communications (2026). https://doi.org/10.1038/s41467-026-75871-3
Image Credits: AI Generated
DOI: 10.1038/s41467-026-75871-3
Keywords: VLA15, Lyme borreliosis, Lyme disease vaccine, OspA, Borrelia burgdorferi, booster dose, vaccine immunogenicity, tick-borne disease, vaccine safety, immune memory
